Literature DB >> 17454841

Lupus anticoagulant is significantly associated with inflammatory reactions in patients with suspected deep vein thrombosis.

J J Sidelmann1, J A Sjøland, J Gram, V Bertelsen, T Mourits-Andersen, H Münster, A M B Münster, J Jespersen.   

Abstract

OBJECTIVE: Lupus anticoagulant (LA) and antiphospholipid antibodies (aPL) are suggested as risk factors for development of deep vein thrombosis (DVT) among patients without systemic lupus erythematosus (SLE). Other conditions, e.g. inflammation, are reported to induce LA and it is uncertain whether the association between LA and DVT is causal. In this study the associations between aPL, LA and inflammation were investigated in 170 consecutive patients without SLE, but with a tentative diagnosis of DVT.
MATERIAL AND METHODS: DVT was diagnosed in 64 patients. LA was determined according to the criteria of the International Society of Thrombosis and Haemostasis. The concentration of anticardiolipin (aCL) and beta(2)-glycoprotein I (anti-beta(2)-GPI) antibodies as well as C-reactive protein (CRP) was determined with sensitive and precise methods.
RESULTS: LA was demonstrated in 8 patients with DVT and in 10 patients without DVT, relative risk 1.33 (CI: 0.55-3.18). No significant association was observed between aCL or anti-beta(2)-GPI and DVT. Patients suffering from DVT had significantly higher concentrations of CRP than patients without DVT. However, CRP was also significantly higher in patients positive for LA than in patients without LA irrespective of the presence of DVT (p<0.001).
CONCLUSIONS: The present study supports a strong association between inflammatory reactions and development of LA in patients with suspected DVT, whereas no significant association was demonstrated between LA or aPL and DVT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17454841     DOI: 10.1080/00365510601038992

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  7 in total

1.  8-isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study.

Authors:  Savino Sciascia; Dario Roccatello; Maria Tiziana Bertero; Debora Di Simone; Domenico Cosseddu; Antonella Vaccarino; Mario Bazzan; Daniela Rossi; Cesar Garcia-Fernandez; Leticia Ceberio; Stefania Stella; Elisa Menegatti; Simone Baldovino
Journal:  Inflamm Res       Date:  2012-05-26       Impact factor: 4.575

2.  Indeterminate lupus anticoagulant results: Prevalence and clinical significance.

Authors:  Khaldoun Alkayed; Kandice Kottke-Marchant
Journal:  Korean J Hematol       Date:  2011-12-27

3.  Elevated plasma level of soluble triggering receptor expressed on myeloid cells-1 is associated with inflammation activity and is a potential biomarker of thrombosis in primary antiphospholipid syndrome.

Authors:  Yonatan Edel; Vitaly Kliminski; Elisheva Pokroy-Shapira; Shirly Oren; Ariela Dortort Lazar; Yael Pri-Paz Basson; Mohammad Egbaria; Yair Molad
Journal:  Arthritis Res Ther       Date:  2019-01-07       Impact factor: 5.156

4.  Correlation between Deep Venous Thrombosis and Inflammation in Patients after Implantation of Permanent Pacemaker.

Authors:  Jianxin Ma; Lian Cui; Wenjin Huo; Guanghui Wang; Xin Quan; Jinping Zhang
Journal:  Iran J Public Health       Date:  2020-01       Impact factor: 1.429

Review 5.  COVID-19, Antiphospholipid Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association?

Authors:  Georges El Hasbani; Ali T Taher; Ali Jawad; Imad Uthman
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2020-12-03

6.  The effect of SARS-Co-V2 infection on prothrombotic and anticoagulant factors in dialysis patients.

Authors:  Anne Riddell; Pratima Chowdary; Andrew Davenport
Journal:  Artif Organs       Date:  2022-03-14       Impact factor: 2.663

7.  Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?

Authors:  Thomas Foret; Virginie Dufrost; Lucie Salomon Du Mont; Patricia Costa; Benjamin Lefevre; Patrick Lacolley; Veronique Regnault; Stephane Zuily; Denis Wahl
Journal:  Curr Rheumatol Rep       Date:  2021-07-03       Impact factor: 4.592

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.